Dr Reddys Laboratories Stock Today
| RDY Stock | USD 81.22 1.15 1.44% |
Performance8 of 100
| Odds Of DistressLess than 3
|
Dr Reddys is trading at 81.22 as of the 26th of July 2024; that is 1.44% increase since the beginning of the trading day. The stock's open price was 80.07. Dr Reddys has a very small chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. Equity ratings for Dr Reddys Laboratories are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of June 2024 and ending today, the 26th of July 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of April 2001 | Category Healthcare | Classification Health Care |
Reddys Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. The company has 166.54 M outstanding shares of which 1.94 M shares are at this time shorted by investors with about 7.38 days to cover. More on Dr Reddys Laboratories
Moving against RDY Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
RDY Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | MARC KIKUCHI | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Pharmaceutical, SPASX All Technology, Obamacare, Healthcare, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsDr Reddys can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Dr Reddys' financial leverage. It provides some insight into what part of Dr Reddys' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dr Reddys Laboratories (RDY) is traded on New York Stock Exchange in USA. It is located in 8-2-337, Road No. 3, Hyderabad, India, 500034 and employs 27,048 people. Dr Reddys is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a total capitalization of 13.67 B. Dr Reddys Laboratories runs under Pharmaceuticals sector within Health Care industry. The entity has 166.54 M outstanding shares of which 1.94 M shares are at this time shorted by investors with about 7.38 days to cover.
Dr Reddys Laboratories has about 2.93 B in cash with 45.43 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 208.58.
Check Dr Reddys Probability Of Bankruptcy
Ownership AllocationDr Reddys Laboratories secures a total of 166.54 Million outstanding shares. About 85.0 % of Dr Reddys outstanding shares are held by general public with 14.98 (percent) by institutions. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check RDY Ownership Details
RDY Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Man Group Plc | 2024-03-31 | 705.6 K | |
| Gqg Partners Llc | 2024-03-31 | 437 K | |
| Grantham, Mayo, Van Otterloo & Co., Llc | 2024-03-31 | 338.8 K | |
| Fisher Asset Management, Llc | 2024-03-31 | 318.4 K | |
| Jpmorgan Chase & Co | 2024-03-31 | 260.1 K | |
| Schroder Investment Management Group | 2024-03-31 | 222.7 K | |
| Millennium Management Llc | 2024-03-31 | 206 K | |
| Acadian Asset Management Llc | 2024-03-31 | 196.2 K | |
| Ameriprise Financial Inc | 2024-03-31 | 185.6 K | |
| Blackrock Inc | 2024-03-31 | 2.2 M | |
| Royal Bank Of Canada | 2024-03-31 | 2.2 M |
Dr Reddys Historical Income Statement
RDY Stock Against Markets
Dr Reddys Corporate Directors
| Leo Puri | Non-Executive Independent Director | Profile | |
| Allan Oberman | Non-Executive Independent Director | Profile | |
| Prasad Menon | Lead Non-Executive Independent Director | Profile | |
| Shikha Sharma | Non-Executive Independent Director | Profile |
Additional Tools for RDY Stock Analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.